Genzyme Signs Diagnostics Deal With Moffitt Cancer Center

Genzyme has entered a license agreement with Moffitt Cancer Center for exclusive worldwide diagnostic rights to the discovery of the relationship of two proteins to patient response to nonsmall cell lung cancer (NSCLC) treatment.

The proteins, RRM1 and ERCC1, have been shown to correlate with patient response to platinum drugs and gemcitabine, both of which are commonly used in treating NSCLC.

Genzyme said it plans to develop a test to measure the expression levels of these proteins in NSCLC patients.